By Kate Hammeke, VP of Market Research, Industry Standard Research (ISR)
Every drug innovator has its own way of choosing service providers and its own way of prioritizing their CDMO selection criteria. These criteria often change from project to project and from sponsor to sponsor. At the same time, there are components of the CDMO selection process that are not influenced by the type of molecule, the stage of development, or the company’s main outsourcing driver. Data from Industry Standard Research’s development and commercial outsourcing models offer insight into the decision-making process, as well as details on why sponsors opt for different contracting approaches, from tactical outsourcing to the use of preferred providers and engaging in strategic partnerships.